Division of Urology, Department of Surgery, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan.
Department of Medicine, National Yang-Ming University, Taipei, Taiwan.
Int Urol Nephrol. 2019 Jul;51(7):1113-1119. doi: 10.1007/s11255-019-02152-y. Epub 2019 May 20.
Androgen deprivation therapy (ADT) use in prostate cancer (PCa) patients has been reported to have an association with rheumatoid arthritis. We aimed to assess the impact of ADT on the subsequent risk of tenosynovitis.
Using data from the National Health Insurance Research Database of Taiwan between 2001 and 2013, 3309 patients with PCa were identified. Among them, 729 ADT patients comprised the study group with 729 matched non-ADT controls. We used a 1:1 propensity score matched analysis. The demographic characteristics and comorbidities of the patients were analyzed; Cox proportional hazards regression was used to calculate the hazard ratios (HR) for the risk of tenosynovitis.
There were 224 (15.3%) patients with newly diagnosed tenosynovitis. Compared with non-ADT patients, ADT patients had a lower risk of subsequent tenosynovitis with an adjusted HR of 0.38 [95% confidence interval (CI) 0.28-0.51; P < 0.001].
ADT use apparently did not increase the risk of tenosynovitis in patients with PCa. Further studies are warranted to assess the clinical significance.
雄激素剥夺疗法（ADT）在前列腺癌（PCa）患者中的应用与类风湿关节炎有关。我们旨在评估 ADT 对随后发生腱鞘炎的风险的影响。
利用台湾 2001 年至 2013 年国家健康保险研究数据库的数据，确定了 3309 例 PCa 患者。其中，729 例 ADT 患者为研究组，与 729 例非 ADT 对照组相匹配。我们使用了 1:1 的倾向评分匹配分析。分析患者的人口统计学特征和合并症；使用 Cox 比例风险回归计算腱鞘炎风险的风险比（HR）。
有 224 例（15.3%）患者新诊断为腱鞘炎。与非 ADT 患者相比，ADT 患者发生腱鞘炎的风险较低，调整后的 HR 为 0.38（95%置信区间 0.28-0.51；P<0.001）。
ADT 的使用显然不会增加 PCa 患者发生腱鞘炎的风险。需要进一步的研究来评估其临床意义。
